Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $94
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $112 to $94.
August 06, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital maintains a Buy rating on CRISPR Therapeutics but lowers the price target from $112 to $94.
The Buy rating suggests continued confidence in CRISPR Therapeutics' long-term potential, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100